On the stock market since 2022, it operates in the world of health and science. It has 1,012 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 100% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $1.3B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 80% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 92% a year on average.
The average analyst price target is $8.60 — 148% above today’s price.
The company’s market value is 39 times its annual profit. Even a small disappointment could hit the price hard.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
On our five-subject report card, ALVO sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: ALVO is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.